Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-10T05:01:08.845Z Has data issue: false hasContentIssue false
  • English
  • Français

Evaluation of the Xpert MTB/RIF Performance on Tissues: Potential Impact on Airborne Infection Isolation at a Tertiary Cancer Care Center

Published online by Cambridge University Press:  15 February 2018

Tracy McMillen ,
Shauna C. Usiak ,
Liang Hua Chen ,
Luz Gomez ,
Peter Ntiamoah ,
Meera R. Hameed ,
Indre Budvytiene ,
Niaz Banaei ,
Mini Kamboj  and
N. Esther Babady
Tracy McMillen
Affiliation:
Clinical Microbiology Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
Shauna C. Usiak
Affiliation:
Infection Control Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
Liang Hua Chen
Affiliation:
Clinical Microbiology Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
Luz Gomez
Affiliation:
Clinical Microbiology Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
Peter Ntiamoah
Affiliation:
Surgical Pathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
Meera R. Hameed
Affiliation:
Surgical Pathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
Indre Budvytiene
Affiliation:
Department of Pathology and Laboratory Medicine, Stanford University Medical Center, Palo Alto, California
Niaz Banaei
Affiliation:
Department of Pathology and Laboratory Medicine, Stanford University Medical Center, Palo Alto, California
Mini Kamboj
Affiliation:
Infection Control Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
N. Esther Babady*
Affiliation:
Clinical Microbiology Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
*
Address correspondence to N. Esther Babady, PhD, D (ABMM), Clinical Microbiology Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 327 East 64th Street, CLM 522, New York, New York (BabadyN@mskcc.org).
Get access Rights & Permissions [Opens in a new window]

Abstract

OBJECTIVES

In this study, we sought to evaluate the performance of the Xpert MTB/RIF (Cepheid) assay for the detection of Mycobacterium tuberculosis (MTB) complex DNA on fresh and formalin-fixed, paraffin-embedded (FFPE) tissue specimens from oncology patients in an area with a low prevalence of tuberculosis. We also aimed to retrospectively assess the potential impact of Xpert MTB/RIF on the duration of airborne infection isolation (AII).

SETTING

A 473-bed, tertiary-care cancer center in New York City.

DESIGN

A total of 203 tissue samples (101 FFPE and 102 fresh) were tested using Xpert MTB/RIF, including 133 pulmonary tissue samples (65.5%) and 70 extrapulmonary tissue samples (34.5%). Acid-fast bacilli (AFB) culture was used as the diagnostic gold standard. The limit of detection (LOD) and reproducibility were also evaluated for both samples types using contrived specimens. The potential impact of the Xpert MTB PCR assay on tissue samples from AII patients on AII duration was retrospectively assessed.

RESULTS

Using the Xpert MTB/RIF for fresh tissue specimens, the sensitivity was 50% (95% CI, 1.3%–98.7%) and the specificity was 99% (95% CI, 94.5%–99.9%). For FFPE tissue specimens, the sensitivity was 100% (95% CI, 63.1%–100%) and the specificity was 98.3% (95% CI, 95.5%–100%. The LOD was 103 colony-forming units (CFU)/mL for both fresh and FFPE tissue specimens, and the Xpert MTB/RIF was 100% reproducible at concentrations 10 times that of the LOD. With an expected turnaround time of 24 hours, the Xpert MTB PCR could decrease the duration of AII from a median of 8 days to a median of 1 day.

CONCLUSIONS

The Xpert MTB/RIF assay offers a valid option for ruling out Mycobacterium tuberculosis complex (MTBC) on tissue samples from oncology patients and for minimizing AII resource utilization.

Infect Control Hosp Epidemiol 2018;39:462–466

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 39 , Issue 4 , April 2018 , pp. 462 - 466
Copyright
© 2018 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

PREVIOUS PRESENTATION. The results of this study were presented in part at the 2016 American Society of Microbiology Microbe Meeting on June 20, 2016, in Boston, Massachusetts.

References

REFERENCES

1. US Food and Drug Admistration. New data show test can help physicians remove patients with suspected TB from isolation earlier. FDA website. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm434226.htm. Published 2015. Accessed January 10, 2018.Google Scholar
2. Luo, RF, Scahill, MD, Banaei, N. Comparison of single-copy and multicopy real-time PCR targets for detection of Mycobacterium tuberculosis in paraffin-embedded tissue. J Clin Microbiol 2010;48:2569–2570.CrossRefGoogle ScholarPubMed
3. Babady, NE, Buckwalter, SP, Hall, L, Le Febre, KM, Binnicker, MJ, Wengenack, NL. Detection of Blastomyces dermatitidis and Histoplasma capsulatum from culture isolates and clinical specimens by use of real-time PCR. J Clin Microbiol 2011;49:3204–3208.CrossRefGoogle ScholarPubMed
4. Garcia-Basteiro, AL, Ismail, MR, Carrilho, C, et al. The role of Xpert MTB/RIF in diagnosing pulmonary tuberculosis in post-mortem tissues. Sci Rep 2016;6:20703.CrossRefGoogle ScholarPubMed
5. Moure, R, Torres, M, Martin, R, Alcaide, F. Direct detection of Mycobacterium tuberculosis complex in clinical samples by a molecular method based on GenoQuick technology. J Clin Microbiol 2012;50:2089–2091.CrossRefGoogle ScholarPubMed
6. Polepole, P, Kabwe, M, Kasonde, M, et al. Performance of the Xpert MTB/RIF assay in the diagnosis of tuberculosis in formalin-fixed, paraffin-embedded tissues. Int J Mycobacteriol 2017;6:87–93.CrossRefGoogle ScholarPubMed
7. Scott, LE, Beylis, N, Nicol, M, et al. Diagnostic accuracy of Xpert MTB/RIF for extrapulmonary tuberculosis specimens: establishing a laboratory testing algorithm for South Africa. J Clin Microbiol 2014;52:1818–1823.CrossRefGoogle ScholarPubMed
8. Vadwai, V, Boehme, C, Nabeta, P, Shetty, A, Alland, D, Rodrigues, C. Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis? J Clin Microbiol 2011;49:2540–2545.CrossRefGoogle ScholarPubMed
9. Moure, R, Martin, R, Alcaide, F. Effectiveness of an integrated real-time PCR method for detection of the Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples in an area of low tuberculosis prevalence. J Clin Microbiol 2012;50:513–515.CrossRefGoogle Scholar
Supplementary material: File

McMillen et al. supplementary material

Tables S1-S4

Download McMillen et al. supplementary material(File)
File 24.6 KB